Skip to Content

Data Release Records Highest Global Clinical Grant Spending- Press Release

Philadelphia, PA - April 16, 2010 - Global clinical grant spending in 2008, the last year for which complete data are available, reached a new high at $11.5 billion. According to TTC,llc, the breakdown by phase ranged from $0.8 billion for phase 1 studies, $2.2 billion for phase 2 studies, and $7.2 billion for phase 3 studies. Phase 4 spending totaled $1.3 billion. The data come from the industry’s largest current database on pharmaceutical clinical grants, GrantPlan®, supplemented with additional data from

Clinical grant spending varied substantially by therapeutic area. The five largest therapeutic areas in phases 1-3 were: Oncology, 23%; Central Nervous System and Mental Disorders, 22%, Cardiovascular diseases, 18%, Endocrine, 10%, and Infectious diseases, 7%. Relative phase 4 spending differed by therapeutic area, with the five largest being: Central Nervous System and Mental Disorder, 40%; Cardiovascular, 20%; Endocrine, 10%, Infectious Diseases, 7%, and Genitourinary Systems, 4%. Oncology grant spending represented only 3% of phase 4 spending.

Contact: Marie Johnston 4548 Market Street, Suite M-20 Philadelphia PA 19139 Ph: 215-243-4103 Fax: 215-243-4001

TTC was founded in 2001 by Dr. Harold Glass, who is the creator of clinical costs benchmarking databases. TTC has their headquarters in Philadelphia, with offices in Chicago and London. With five distinctive database products, TTC has the largest current database of investigator site budgets from 60 countries. TTC combines a strong financial base, a global reach, and an experienced team of customer-focused professionals proud to serve the industry in the management of costs and speed of clinical trials. With nearly 100 clients who conduct over 75% of the clinical trials around the world, TTC stands ready to serve all companies with specific programs tailored to meet their customized requirements. Visit <> to learn more.




Posted: April 2010